Article
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jul 2011
Vollebergh M A, Lips E H, Nederlof P M, Wessels L F A, Schmidt M K, van Beers E H, Cornelissen S, Holtkamp M, Froklage F E, de Vries E G E, Schrama J G, Wesseling J, van de Vijver M J, van Tinteren H, de Bruin M, Hauptmann M, Rodenhuis S, Linn S C
Abstract excerpt
BACKGROUND: Breast cancer cells deficient for BRCA1 are hypersensitive to agents inducing DNA double-strand breaks (DSB), such as bifunctional alkylators and platinum agents. Earlier, we had developed a comparative genomic hybridisation (CGH) classifier based on BRCA1-mutated breast cancers. We hypothesised that this BRCA1-like(CGH) classifier could also detect loss of function of BRCA1 due to other causes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.